December 17, 2025 09:57 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns | Market update: Sensex tumbles 120 points, Nifty below 25,850 at closing bell | ‘Won’t apologise’: Prithviraj Chavan stands firm on controversial Operation Sindoor remark despite backlash | India summons Bangladesh High Commissioner after provocative 'seven sisters' remark | Amazon eyes $10 billion investment in OpenAI — a gamechanger for AI industry! | Goa nightclub fire horror: Luthra brothers brought back to India from Thailand, arrested | Messi chaos costs minister his job: Aroop Biswas resigns after Salt Lake Stadium fiasco | Bengal SIR draft list out: Around 58 lakh voters’ names dropped | Relief for Sonia, Rahul Gandhi as Delhi court refuses to act on ED chargesheet in National Herald case | Centre moves to replace MGNREGA with 'G Ram G', sets stage for winter session showdown
UNI

India records 48,900 new COVID-19 cases, death toll touches 31358

| @indiablooms | Jul 25, 2020, at 03:23 pm

New Delhi: India registered 48,916 new COVID-19 cases in the past 24 hours while the death toll due to the highly infectious disease now stands at 31358, as per Ministry of Health data released on Saturday.

Meanwhile, the number of COVID-19 cases in the country now stands at 1,336,861.

There are 456071 active cases in the country at present.

So far, 849431 people have recovered from the disease.

COVAXIN human trial begins:

The clinical trial of the country's first indigenously-developed vaccine against Novel Coronavirus - COVAXIN began at AIIMS here on Friday, with the first dose of the injection given to a man, nearing his 30s.

According to Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS and principal investigator of the study, ''We had called two people for the human trial, but only one of them turned up.''

Prof Rai said after administering the medicine, the person was put under observation for two hours. No side effect of the vaccine was noted, he added.

His health will be monitored for the coming two weeks, said the Medico, adding that other volunteers will be administered the vaccine on Saturday.

All the volunteers chosen for the two-phase study are healthy people, with no underlying conditions, such as Diabetes or Blood Pressure, Prof Rai said, adding that the study will check the number of antibodies produced after administering of the vaccine.

Total 1,125 people will be administered the vaccine, being formulated jointly by Bharat Biotech, the Indian Council of Medical Research (ICMR) and the National Institute of Virology, Pune.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.